1 active not recruiting, 1 recruiting, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Terminated 1 |
Follow TAK-243: new trials by email Literature Review of TAK-243 trials Research Report on TAK-243
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Studying TAK-243 in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 95 | 2025-03-24 | 2026-10-13 |
| TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2025-03-12 | 2026-11-12 |
| A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors MLN7243 - Advanced Malignant Solid Tumors | Phase 1 | Terminated | Millennium Pharmaceuticals, Inc. | 29 | 2014-01-31 | 2019-03-14 |
Anemia, Refractory, with Excess of Blasts (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1)
National Cancer Institute (NCI) (2) · Millennium Pharmaceuticals, Inc. (1)
United States (3) · Canada (1)
Guillaume Richard-Carpentier (1) · Sarah Shin, MD (1)
UM1CA186644 (1)